NEW YORK — Drug maker Eli Lilly is pleading guilty to a charge that it illegally marketed anti-psychotic drug Zyprexa for off-label use, and will......
Recommended Sources
Recommended Publications
About Pharma Industry
BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.
Web Buzz:
-
Eli Lilly to pay $1.4 billion to settle Zyprexa suits
MarketWatch - 312 days 19 hours 17 minutes ago
LONDON (MarketWatch) -- Eli Lilly & Co. on Thursday reached a deal to pay $1.4 billion and plead guilty to a federal misdemeanor charge over...
-
Eli Lilly to Pay $1.42 Billion to Resolve Drug Probes
Reuters -
312 days 19 hours 5 minutes ago
(Reuters) - Eli Lilly and Co said it will pay about $1.42 billion to settle both criminal and civil investigations related to the marketing of its...
-
Eli Lilly to pay $1.42 billion to resolve Zyprexa probes
Reuters -
312 days 17 hours 4 minutes ago
BOSTON (Reuters) - Eli Lilly and Co said on Thursday it will pay about $1.42 billion to settle criminal and civil investigations into the marketing...
-
Lilly to pay $1.4B in Zyprexa settlement
Fierce Pharma -
312 days 15 hours 33 minutes ago
The long rumored settlement between Eli Lilly and the Department of Justice is a done deal. The drugmaker will pay $1.4 billion to take care of...
-
Eli Lilly to pay $1.42-billion to settle Zyprexa probes
Globe and Mail - 312 days 6 hours 51 minutes ago
Eli Lilly and Co. said yesterday it will pay about $1.42-billion (U.S.) to settle criminal and civil investigations into the marketing of its...
- Bankers Reveal Top Biotech IPO Contenders; New Filer Ironwood Among Them
- Pfizer Got $160M in Tax Money to Build in Connecticut
- Sanofi's Viehbacher Backs Health Reform; May Change Company's Name
- Viagra Now Available Intravenously
- Genzyme Kidney Drug Failed, Too...What Could Possibly Happen Next?
- Peter Pitts' CMPI Targeted Over Anti-Healthcare Reform Video Game
- Why Allergan and Medicis Should Embrace the "Botox Tax" in Senate Health Bill
- Why J&J's Stelara Launch Should Target Dermatologists First
- NHS Loses Fight Over Publication of Antipsychotic Meds Brochures for Kids
- Genzyme's Termeer Got $50M in Compensation Over Last 3 Years; Wife Got Trips to Asia on Corporate Jet
- Merck Gives Snapshot of Combined Company: $47B in Sales; Just $7.6B in Cash
- Why Pfizer Wants Your Car-Sick Dog to Travel on Thanksgiving
- FDA Delays Genzyme's Lumizyme, Manufacturing Problems Blamed
- The Business Conundrums of Trying to Prevent Cancer
- Pfizer Scientist Stabbed Wife After Job Loss, Police Say
- Will FDA Approve MannKind's Insulin Inhaler?
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- Hepatitis C Drugs Kill the Virus...and Your Sex Drive
- Microchip Implant to Link Your Health Records, Credit History, Social Security
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- NYT's MannKind Story Needlessly Quoted a Competitor Bashing Afresa
- Novartis CEO Sends Emails to 140 Animal Rights Activists:
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
- How NOT to Write a Biotech Press Release: Just Ask Epeius
- The 10 Weirdest Drug Stories of the Month
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity"
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone
Industry Transcripts by Seeking Alpha
- How to choose the right insurance carrier for your business
- Real Estate: Prepare your properties to weather what lies ahead
- Technology: Be prepared if part of your global supply chain goes missing
BNET User Analysis